Fertility Key Pen (Kisspeptin) 5mg
Understanding Kisspeptin:
This product is a reusable pen system, which uses refill cartridges for precise and convenient delivery.
Product Strength: 5mg per 3ml cartridge
Storage: Keep refrigerated between 2–8 °C (36–46 °F) to maintain potency and stability.
What It Is
Kisspeptin is a naturally occurring neuropeptide that is being investigated in clinical research for reproductive disorders. While it has been administered in controlled clinical trials, it is not FDA-approved for general therapeutic use outside of research settings. The following information is for educational and research purposes only. Kisspeptin should only be used under the supervision of a qualified healthcare provider in an appropriate clinical or research setting.
Description
Kisspeptin is a naturally occurring neuropeptide encoded by the KISS1 gene, which was originally discovered as a metastasis suppressor in malignant melanoma cells. It is a member of the RFamide peptide family, characterized by a common Arg-Phe-NH₂ motif at the C-terminus. The KISS1 gene produces a 145-amino acid precursor protein that is proteolytically cleaved to generate several biologically active fragments of varying lengths: kisspeptin-54 (the primary endogenous form, also known as metastin), kisspeptin-14, kisspeptin-13, and kisspeptin-10.
Kisspeptin-10 is the shortest endogenous fragment and the most commonly used variant in biomedical research. It retains full receptor-binding activity and potency equivalent to the longer forms, as the C-terminal 10-amino acid region with amidation is critical for receptor activation.
Mechanism of Action
Kisspeptin acts as a master regulator of the reproductive axis by binding to and activating the G protein-coupled receptor GPR54 (also known as KISS1R or AXOR12).
Upon receptor activation, kisspeptin stimulates the release of gonadotropin-releasing hormone (GnRH) from hypothalamic neurons. GnRH then acts on the pituitary gland to trigger the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn regulate sex hormone production (testosterone in males, estradiol in females) and gametogenesis.
This places kisspeptin at the top of the hypothalamic-pituitary-gonadal (HPG) axis hierarchy, acting as a critical gatekeeper for puberty onset and reproductive function throughout life.
Additional Pathways:
Kisspeptin and its receptor are also expressed in the pituitary gland, suggesting a potential direct effect on pituitary hormone secretion independent of hypothalamic GnRH.
Recent research has identified a population of GnRH neurons in the olfactory bulb that express kisspeptin receptors, providing a potential pathway for non-invasive intranasal administration.
Key Research Applications & Uses
Clinical Research Applications (Human Studies):
Hypogonadotropic hypogonadism: Kisspeptin administration has been shown to stimulate gonadotropin release in patients with this condition caused by GnRH deficiency.
Hypothalamic amenorrhea: Intranasal kisspeptin successfully stimulated LH release in women with this common reproductive disorder (30% of secondary amenorrhea cases) without adverse effects.
Female infertility: Being investigated as a potential trigger for oocyte maturation in IVF therapy, potentially with lower risk of ovarian hyperstimulation syndrome (OHSS) compared to hCG.
Delayed puberty: Kisspeptin is being studied as a diagnostic and therapeutic tool for adolescents with delayed pubertal onset.
Sexual dysfunction: Early studies suggest potential benefits for low libido and sexual function in both men and women.
Polycystic ovary syndrome (PCOS): Being explored as a potential therapeutic agent.
Metabolic disorders: Emerging evidence suggests potential applications in obesity-related and diabetes-related hypogonadism.
Contraindicated Applications:
Chronic, high-dose administration of kisspeptin causes desensitization with suppression of the HPG axis, which is being explored therapeutically for sex hormone-dependent malignancies (e.g., prostate, breast cancer).
Contraindications & Precautions
Kisspeptin is contraindicated or requires extreme caution in the following populations:
Hormone-sensitive cancers: Individuals with known breast, ovarian, endometrial, prostate, or other hormone-dependent malignancies should avoid kisspeptin, as it may theoretically influence tumor behavior through sex hormone modulation.
Pregnancy: Contraindicated due to unknown effects on fetal development and the delicate hormonal balance required during gestation.
Adolescents: May disrupt normal pubertal progression and timing; use only in controlled research settings.
Cardiovascular disease: Individuals with uncontrolled hypertension, history of syncope, or cardiovascular conditions should be cautious, as kisspeptin can affect blood pressure and heart rate.
Pituitary or hypothalamic disorders: Should undergo full endocrine workup before considering kisspeptin use.
Unexplained irregular menses or undiagnosed infertility: Not a DIY diagnostic tool; requires proper medical evaluation.
Children: Safety and efficacy not established.
Adverse Reactions & Side Effects
Common Side Effects (Reported in Controlled Studies):
Transient flushing: Feeling of warmth or redness, especially in the face.
Mild headaches.
Nausea.
Lightheadedness or dizziness during or shortly after dosing.
Local injection site reactions: Redness, mild swelling, tenderness, or itching (with subcutaneous administration).
Important Safety Notes:
Side effects are typically mild and self-limited in controlled clinical studies with pharmaceutical-grade material.
The "well-tolerated" designation in research applies to specific doses, populations, and durations under medical supervision.
No side effects or adverse events were encountered in the recent intranasal kisspeptin clinical trial.
Research-grade or underground products from unregulated suppliers may carry additional risks due to impurities, endotoxins, and lack of quality control.
Unknown Risks (Long-Term Safety):
Chronic, repeated use has not been well studied in diverse populations.
Persistent overstimulation of the HPG axis could theoretically alter menstrual patterns, sperm production, or sex hormone balance; reversibility is not clearly defined.
Kisspeptin pathways are expressed in multiple tissues, including those involved in metastasis and vascular biology; long-term effects at real-world doses are unknown.
Disclaimer:
This information is for general knowledge and educational purposes only and does not constitute medical advice. Always consult with a qualified medical professional regarding any cosmetic or medical procedure.
